Bluebird bio Inc ( (BLUE) ) has released its Q3 earnings. Here is a breakdown of the information Bluebird bio Inc presented to its investors.

Kebilidi is the first approved gene therapy that can be directly administered to the brain. Its OK secures a priority review ...

Bluebird bio Inc., which nine years ago was worth nearly as much as the airline JetBlue, said it's now looking for enough ...

A team of horticulturists, bio-breeders and agriculture specialists affiliated with a host of institutions across China has ...

Bluebird reports 17 people with sickle cell disease started receiving Lyfgenia gene therapy, with 35 starting Zynteglo for ...

Bluebird Bio (BLUE) Company Description: bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and ...

SOMERVILLE, Mass., November 14, 2024--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today reported third quarter results and business highlights for the quarter ended September ...

SOMERVILLE, Mass. (AP) — SOMERVILLE, Mass. (AP) — Bluebird Bio Inc. (BLUE) on Thursday reported a loss of $60.8 million in its third quarter. On a per-share basis, the Somerville, Massachusetts-based ...

Find out what is driving the slowdown in gene therapy investment, as the sector continues to struggle with widespread layoffs ...

Research analysts at StockNews.com assumed coverage on shares of bluebird bio (NASDAQ:BLUE – Get Free Report) in a research ...

Inc. ("bluebird bio" or the "Company") today announced that it partially adjourned its annual meeting of stockholders ("Annual Meeting") on Wednesday, November 6, 2024, to allow the Company to solicit ...

Casgevy's closest competitors are Bluebird Bio’s Zynteglo and Lyfgenia, which also utilize gene therapy technologies to treat TDT and SCD. In 2019, Zynteglo received conditional marketing ...